Market Overview

Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care

Share:

Erlanger Health System, a multi-hospital health system based in
Tennessee have announced a partnership with Viz.ai., a leading applied
artificial intelligence company, to transform stroke care. The
Erlanger Stroke Center
is one of the foremost stroke centers in the
nation.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180725005405/en/

Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care ...

Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care (Photo: Business Wire)

Erlanger has partnered to use Viz LVO, a cloud-based artificial
intelligence system that can automatically analyze CT scans for
suspected large vessel occlusions (LVOs), along with Viz CTP into its
clinical workflow. After a patient undergoes a CT scan, Viz LVO alerts
the stroke specialist of a suspected LVO, allowing the specialist to
proactively review the images on their smartphone. Analysis, performed
by deep learning algorithms, is automatic and occurs in minutes. Viz
LVO is the only stroke triage software to receive FDA clearance.

Erlanger anticipates that Viz LVO will improve the stroke pathway in one
of the largest and busiest stroke programs in the United States by
reducing treatment times and increasing patient access to potentially
life-savings therapies such as mechanical thrombectomy. Earlier
diagnosis and faster transfer to an interventional stroke center for
advanced stroke treatment has the potential to improve patient outcomes.

"There is no more time-sensitive treatment in all of medicine than that
required when responding to stroke," said Dr. Thomas G. Devlin,
Executive Medical Director, University of Tennessee Erlanger Neurology
and Co-Director of the Erlanger Southwest Regional Stroke Center. "Viz
LVO combines ground breaking AI with frictionless communication. It
provides the resources to help shave off critical minutes, even hours,
in the triage, diagnosis and treatment of stroke and allows stroke
specialists to be proactive rather than reactive. Viz LVO facilitates
fast and accurate detection and referral of large vessel occlusion
strokes enabling better collaboration between the stroke teams at
comprehensive and referral hospitals."

Erlanger Health System will roll out Viz LVO across the Erlanger
network, followed by expansion to the rest of their referral network.

"Viz.ai transforms stroke care not only for our patients, but for the
entire region," said Joseph Winick, FACHE, Lead Executive, Erlanger
Innovation Center at Erlanger Health System. "Viz LVO allows us to
deliver the right care in the right place, potentially improving
outcomes, while lowering cost. Viz LVO provides an AI platform to drive
ROI".

About Stroke

Stroke is a leading cause of permanent disability, death and healthcare
costs globally. According to the American Heart Association/American
Stroke Association (AHA/ASA), stroke is the fifth leading cause of death
in the U.S. and a leading cause of disability. When a stroke occurs, and
the flow of oxygen-rich blood to a portion of the brain is blocked, two
million brain cells die every minute; in the case of stroke, "time is
brain."

About Viz.ai, Inc.

Viz.ai, Inc is emerging as the leader in applied artificial intelligence
in healthcare. Their mission is to fundamentally improve how healthcare
is delivered in the world, through intelligent software that promises to
reduce time to treatment and improve access to care.

Their flagship product, Viz LVO, leverages advanced deep learning to
communicate time-sensitive information about stroke patients straight to
a specialist who can intervene and treat.

In February 2018, the U.S. Food and Drug Administration (FDA) granted a
De Novo clearance for Viz LVO, the first-ever computer-aided triage and
notification platform. Most recently, Viz.ai announced its second FDA
clearance for Viz CTP through the 510(k) pathway, offering healthcare
providers an important tool for automated cerebral image analysis.

Viz.ai are located in San Francisco and Tel Aviv and backed by leading
Silicon Valley investors, including Kleiner Perkins, Google Ventures,
Innovation Endeavors and DHVC.

To find out more, visit http://www.Viz.ai,
follow us on Twitter or find us on LinkedIn.

Viz LVO and Viz CTP indications of use can be found at https://www.viz.ai/indications-for-use/.

View Comments and Join the Discussion!